

RESEARCH

Open Access

# NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma

Giulio Fiaschetti<sup>1</sup>, Christina Schroeder<sup>3</sup>, Deborah Castelletti<sup>1</sup>, Alexandre Arcaro<sup>3</sup>, Frank Westermann<sup>2</sup>, Martin Baumgartner<sup>1</sup>, Tarek Shalaby<sup>1</sup> and Michael A Grotzer<sup>1\*</sup>

## Abstract

Medulloblastoma (MB), the most common pediatric malignant brain cancer, typically arises as pathological result of deregulated developmental pathways, including the NOTCH signaling cascade. Unlike the evidence supporting a role for NOTCH receptors in MB development, the pathological functions of NOTCH ligands remain largely unexplored. By examining the expression in large cohorts of MB primary tumors, and in established *in vitro* MB models, this research study demonstrates that MB cells bear abnormal levels of distinct NOTCH ligands. We explored the potential association between NOTCH ligands and the clinical outcome of MB patients, and investigated the rational of inhibiting NOTCH signaling by targeting specific ligands to ultimately provide therapeutic benefits in MB. The research revealed a significant over-expression of ligand JAG1 in the vast majority of MBs, and proved that JAG1 mediates pro-proliferative signals via activation of NOTCH2 receptor and induction of HES1 expression, thus representing an attractive therapeutic target. Furthermore, we could identify a clinically relevant association between ligand JAG2 and the oncogene MYC, specific for MYC-driven Group 3 MB cases. We describe for the first time a mechanistic link between the oncogene MYC and NOTCH pathway in MB, by identifying JAG2 as MYC target, and by showing that MB cells acquire induced expression of JAG2 through MYC-induced transcriptional activation. Finally, the positive correlation of MYC and JAG2 also with aggressive anaplastic tumors and highly metastatic MB stages suggested that high JAG2 expression may be useful as additional marker to identify aggressive MBs.

**Keywords:** Medulloblastoma, NOTCH, JAG1, JAG2, Pediatric cancer

## Introduction

Medulloblastoma (MB) is the most common pediatric malignant brain cancer, accounting for approximately 20% of primary central nervous system neoplasms in this age group [1]. Because of the significant rate of mortality and treatment-related morbidity, further understanding of the molecular biology of MB is needed to improve current treatment regimens and discover novel and more effective molecular-targeted therapies. Four distinct MB subgroups have been identified based on common molecular alterations: WNT tumors are characterized by activated Wntless pathway and carry a favorable prognosis under current treatment regimens; SHH tumors, which possess active Sonic Hedgehog signaling, and Group 4 tumors,

molecularly less well characterized, have an intermediate prognosis; Group 3 tumors are characterized by high levels of the oncogene MYC and associated with poor prognosis [2]. A molecular-based classification of MB is a crucial step towards optimized treatment schemes aiming at improving risk-benefit therapeutic profiles. One further layer of complexity is the identification of key biological alterations to be selectively targeted by tailored therapies.

MBs are heterogeneous cerebellar tumors, which commonly arise as the pathological result of deregulated developmental pathways, including the NOTCH cascade [3,4]. NOTCH signaling is required for the physiological development of the cerebellum during embryogenesis, controlling cell differentiation, proliferation, and apoptosis [5]. NOTCH cascade involves functionally non-redundant genes that appear to exert unique and specific functions [6]. Activation of the canonical NOTCH cascade requires the interaction of ligands (JAG1, JAG2, DLL1, DLL3, and

\* Correspondence: Michael.Grotzer@kispi.uzh.ch

<sup>1</sup>Department of Oncology, University Children's Hospital of Zurich, Zurich, Switzerland

Full list of author information is available at the end of the article

DLL4) with receptors (NOTCH 1-4) [7]. Ligand binding triggers the proteolytic cleavage of NOTCH receptors, which is mediated by distinct enzymes, including  $\gamma$ -secretase. Once released into the cytoplasm, the NOTCH intracellular domain (NICD) translocates into the nucleus and activates a series of transcriptional regulatory events with context-dependent phenotypic consequences [7]. The spatial and temporal expression of receptors and ligands results in diverse heterogeneous cellular responses that can be cell- and tissue-specific, due to cross-talk with other pathways and the cellular microenvironment [8,9]. A growing body of evidence suggests that the ligands also have an intrinsic signaling activity, independent of canonical NOTCH, which may account for the pleiotropic effects of the NOTCH signaling [10].

Deregulation of NOTCH receptors and ligands has been described in a wide variety of human tumors, including pediatric malignancies, such as leukemia, glioblastoma, and neuroblastoma [11-15]. Given the important role of NOTCH signaling in both normal and pathologic cerebellum development, it is not surprising that defects in this pathway are also associated with MB development. In particular, oncogenic properties of NOTCH2 receptor have been associated with MB tumor proliferation, and high expression of the best-characterized NOTCH target gene, *HES1*, has been associated with poor clinical outcome [16,17]. However, to date the potential pathological functions of NOTCH ligands in MB remain largely unexplored. We hypothesized that the abnormal expression of NOTCH ligands in MB cells could trigger an alteration of the NOTCH cascade. Therefore, we investigated NOTCH ligands expression in MB primary samples and in *in vitro* MB models, we examined the potential association between NOTCH ligands and the clinical outcome of MB patients, and explored the rational of inhibiting NOTCH signaling by targeting specific ligands to ultimately provide therapeutic benefits in MB.

## Materials and methods

### Human MB primary samples and human-derived MB cell lines

The tumor material used in this study originates from archival MB samples from patients treated at the University Children's Hospital of Zürich, Switzerland ( $n = 47$ , formalin-fixed paraffin-embedded MB samples). All tissue specimens used were obtained from the Swiss Pediatric Oncology Group (SPOG) Tumor Bank. Written informed consent was obtained from each patient by the hospital that provided the tissue samples. The use of SPOG Tumor Bank tissue samples for cancer research purposes was approved by the Ethical Review Board of Zurich (Ref. Nr. StV-18/02). MB cell lines were cultured as previously published [18,19] and maintained at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. DAOY human MB cells were

purchased from the American Type Culture Collection (ATCC - Manassas, VA, USA). D341, D425, UW-228-2, and Med-1 human MB cells were the kind gift of Dr. Henry Friedman (Duke University, Durham). The stable clones DAOY V11 (empty vector transfected) and DAOY M2.1 (MYC vector transfected) were maintained in selective medium in the presence of 500 mg/ml G418 [20]. MB cells were grown as neuro-spheres in neurobasal medium added with B-27 Supplement (GIBCO - Life Technologies Grand Island, NY, USA), recombinant human EGF (20 ng/ml), and basic FGF (10 ng/ml) (R & D Systems Inc., Minneapolis, MN 55413 USA) in corning ultra-low binding 24-well plates (Sigma-Aldrich, St. Louis, MO, USA).

### Gene expression profiling studies of MB primary samples

MB expression profiles were generated on Affymetrix 133A [21]; Affymetrix 133plus 2.0 [22,23]; Affymetrix Human Gene 1.1 ST [24]; or Affymetrix exon 1.0 arrays [25,26]. The datasets used in this study were comparable regarding most patient characteristics [27]. The human normal cerebellum expression profile was generated with Affymetrix 133plus 2.0 [28]. Data are accessible through the open access platform R2 for visualization and analysis of the microarray data (<http://r2.amc.nl>).

### RNA analysis by qRT-PCR

Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Basel, Switzerland) following the manufacturer's instructions. After enzymatic digestion of DNA with RNase-free DNase (Qiagen), 0.5-1  $\mu$ g of total RNA was used as the template for reverse transcription employing random hexamer primers and the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems - Life Technologies Grand Island, NY, USA). For the qRT-PCR reaction, Gene Expression Master Mix (Applied Biosystems) was used, and the protocol was optimized for the ABI7900HT reader (Applied Biosystems). Probe-primer solutions specific for the following genes (purchased from Applied Biosystems) were used: *MYC* (Hs00153408\_m1), *JAG2* (Hs00171432\_m1), *JAG1* (Hs01070032\_m1), and *HES1* (Hs00172878\_m1). Normal human adult cerebellum mRNA samples (Clontech-Takara Bio Europe, Saint-Germain-en-Laye, France) (R12340039-50, AMS Biotechnology Limited, 184 Park Drive, Milton Park, Abingdon OX14 4SE, UK.) and normal human fetal (40 weeks) cerebellum mRNA samples (R1244039-50, AMS Biotechnology) were used as a reference. The relative gene expression was calculated for each gene of interest using the  $\Delta\Delta$ CT method, in which cycle threshold (CT) values were normalized to the housekeeping genes *succinate dehydrogenase complex subunit A (SDHA)* (Hs00188166\_m1) and *18 s* (Hs99999901\_s1).

### ChIP-on-chip analysis

Genomic DNA was extracted and precipitated with a MYC-specific antibody to enrich MYC-binding promoter sequences, which were hybridized to a promoter oligo-array as previously described [29]. The genomic positions for probes and their enrichment ratios are provided for MYC at the *JAG2* locus. The horizontal red line indicates the median enrichment ratio for MYC versus the input, as calculated from all probes for chromosome 14.

### Western blot analysis

Total protein extracts were obtained from  $0.5\text{--}1.5 \times 10^6$  cells lysed with RIPA buffer (50 mM Tris-Cl, pH 6.8, 100 mM NaCl, 1% Triton X-100, 0.1% SDS) supplemented with Complete Mini Protease Inhibitor Cocktail (Roche-Applied Sciences) and the phosphatase inhibitors  $\beta$ -glycerophosphate (20 mM) and  $\text{Na}_3\text{VO}_4$  (200  $\mu\text{M}$ ). Proteins were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and blotted on PVDF membranes (GE Healthcare, Chalfont St Giles Buckinghamshire, UK) or Trans-Blot Turbo 0.2- $\mu\text{m}$  nitrocellulose (Bio-Rad Laboratories, Inc., Hercules, CA 94547, USA). After binding of the primary antibodies, the signal was detected by chemiluminescence using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce-ThermoScientific, Rockford, IL, U.S.A.). Antibody specific for Hes1 (H-140) (sc-25392) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz Biotechnology, Inc. Santa Cruz, CA, U.S.A.); antibody specific for the Notch2 intracellular domain (Asp1733) (ab52302) was purchased from Abcam (Abcam plc, Cambridge, UK); antibodies specific for Jagged-2 (C23D2) (2210), JAG1 (28H8) (2620), cleaved Notch1 (Val1744), and MYC (9402) were obtained from Cell Signaling Technology (Cell Signaling Technology, Danvers, MA, U.S.A.). As a loading control,  $\beta$ -actin (Sigma-Aldrich, St. Louis, MO, U.S.A.) was detected by chemiluminescence using Pierce ECL Substrate (Pierce-ThermoScientific).

### siRNA transfection

Cells were transfected when they reached 70–80% confluence in 6-well plates using either SMARTpool small interfering RNA (siRNA) specific for *JAG2* (L-017187-00), *JAG1* (L-011060-00), and *MYC* (L-003282-00) or siCONTROL non-targeting siRNA pool (D-001810-10-05) as a control (Dharmacon, Thermo Fisher Scientific, Waltham, MA). Each pool of siRNA was used at the final concentration of 50 nM in combination with Dharmafect 4 as the transfection reagent (Dharmacon) according to the manufacturer's instructions. After 24, 48, and 72 hours, the cells were harvested for both mRNA and protein extraction to assess gene expression by quantitative real-time PCR (qRT-PCR) and immunoblotting, respectively.

### Cell viability, proliferation, and apoptosis analysis

Viability of MB cells was evaluated using the CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega Corporation, Madison, WI, USA) and cell proliferation reagent WST-1 (05015944001) (Roche Diagnostics, Rotkreuz, Switzerland). Additionally, the number of viable cells was determined by trypan blue exclusion using a hemocytometer. Proliferation was quantified using the chemiluminescence-based Cell Proliferation ELISA BrdU kit (Roche Diagnostics). Activation of caspases 3 and 7 was detected using the Caspase-Glo 3/7 Assay (Promega Corporation). Histone-associated DNA fragments were quantified using Cell Death Detection ELISAPLUS assays (Roche Diagnostics). Data are expressed as the average values obtained from three independent experiments.


### Statistical analysis

All experiments were performed at least in triplicate. Data are represented as the mean  $\pm$  s.d. For *in vitro* experiments, a Student's t-test was used. P-values of  $<0.05$  were considered significant. Pearson's correlation test was used for gene correlation in patient samples. Student's unpaired T and Mann-Whitney tests were applied for statistical analysis of normally and non-normally distributed samples, respectively [ $* < 0.05$ ,  $** < 0.01$ ,  $*** < 0.001$ ].

## Results

### NOTCH ligands are aberrantly expressed in medulloblastoma

We first addressed whether MB tumors express predominantly one or more of the five known NOTCH ligands. By analyzing their expression in three distinct publicly available gene expression profiles of primary MBs (total of 195 cases), we showed that tumors samples express all five NOTCH ligands, with *JAG1* showing the highest expression levels compared to the other ligands (Figure 1a and Additional file 1: Figure S1a). The levels of *JAG2*, *DLL1*, and *DLL3* were comparable to each other, whereas that of *DLL4* was relatively lower. Our hypothesis that MB tumors bear aberrant levels of NOTCH ligands was verified when the expression levels in tumors were normalized to expression in normal cerebella (Figure 1b–f). The analysis revealed distinct significant aberrancies in the level of four ligands: *JAG1*, *JAG2*, *DLL1*, and *DLL4*. We observed an over-expression of *JAG1* and *DLL1* (Figure 1b and d, respectively) and a down-regulation of *JAG2* and *DLL4* (Figure 1c and f, respectively), whereas *DLL3* expression in MB tumor samples was comparable to that in cerebellum controls (Figure 1e). The most relevant change in expression was that of NOTCH ligand *JAG1*, which was significantly overexpressed in almost all MBs (189/195), compared to cerebellum. To a lesser extent, also the up-regulation of *DLL1*, as well as the reduced expression of *JAG2* and of



**Figure 1** Expression of NOTCH ligands in MB primary tumors. (a) Relative mRNA expression of the indicated NOTCH ligands in a representative gene expression dataset of 62 human MB tumors [23]. Dot plots showing relative expression of *JAG1* (b), *JAG2* (c), *DLL1* (d), *DLL3* (e), and *DLL4* (f) in three independent gene expression datasets of human MB tumors: 62 samples [23]; 57 samples [22]; 76 samples [26].

*DLL4*, appeared to be common features of MB tumors. Notably, the variance of sample distribution was smaller for *JAG1* and *JAG2*, both in MB tumors and control samples, whereas the expression levels of *DLL1*, *DLL3*, and *DLL4* demonstrated greater variation (Figure 1a and Additional file 1: Figure S1a and b). Together these findings confirmed that MB tumors harbor abnormal levels of distinct NOTCH ligands, which likely results in a broad alteration of the fine-tuning regulation of the signaling pathway.


#### JAG1 is a survival factor mediating activation of canonical NOTCH2 signals in medulloblastoma

Because of the relevant broad over-expression of *JAG1* in MB primary samples, we focused this section of the research on the analysis of the biological role of this specific NOTCH ligand. To validate the up-regulation observed in MB gene expression profiles, *JAG1* mRNA levels were quantified in an additional independent cohort of 47 MB primary samples collected at the Children's Hospital of Zurich. Consistent with the previous findings, *JAG1* was overexpressed in 74% (35/47) of MB cases compared to normal cerebellum (Figure 2a). These findings were further verified by analyzing the protein and mRNA levels in a representative panel of human-derived MB cell lines. Four out of five cell lines overexpressed *JAG1* compared to normal cerebellum (Figure 2b), confirming that MB

cells bear aberrantly high levels of NOTCH ligand *JAG1*, also in established and characterized MB models. Notably, D341 MB cell line, which is genetically similar to tumors of the molecular Group 3 [30], showed a lower *JAG1* expression level compared to the others (Figure 2b).

To determine whether the activation of the canonical NOTCH pathway in MB is mediated by *JAG1*, we quantified the levels of activated NOTCH receptors (NICD) and of the NOTCH target gene (*HES1*) in MB cells upon *JAG1* depletion. siRNA-mediated silencing of *JAG1* (Figure 2c and Additional file 2: Figure S2a) caused a drastic reduction in NICD2 and *HES1* expression, at the protein and mRNA levels (Figure 2c and d, respectively), suggesting an important role for *JAG1* in canonical NOTCH2 signaling activation. These results were further confirmed by comparative gene expression analysis of clinical MB samples, which showed a highly significant positive association between *JAG1* and *HES1* mRNA transcript levels (Figure 2e and Additional file 2: Figure S2b). Notably, NOTCH1 receptor did not appear to be affected by *JAG1* depletion, since no relevant changes in NICD1 abundance could be detected (Additional file 2: Figure S2c). Therefore, these results depict *JAG1* as important activator of pro-proliferative NOTCH2 cascade [17], and link a specific ligand to the level of *HES1*, whose high expression has been associated with poor prognosis [16,17]. Furthermore, without affecting NOTCH1, which





**Figure 2 JAG1 mediates pro-survival signaling through activation of canonical NOTCH2 signaling.** (a) Relative *JAG1* expression in 47 fresh frozen MB primary samples. Values represent the fold-change in *JAG1* mRNA expression compared to that in normal cerebellum samples (defined as 1). (b) *JAG1* mRNA (upper panel) and protein (lower panel) expression in the indicated MB cell lines. mRNA values represent the fold-change in *JAG1* mRNA expression compared to that in normal cerebellum samples (defined as 1). (c) Protein expression of *JAG1*, *NICD2*, and *HES1* in DAOY cells at 72 hours after treatment with *JAG1* siRNA compared to control siRNA. (d) *HES1* mRNA relative expression in DAOY cells upon *JAG1* siRNA treatment at the indicated time-points. Values represent the percent decrease in *HES1* mRNA relative to the control. (e) Correlation between *JAG1* and *HES1* mRNA expression in a dataset of 103 MB tumors [25].  $r$ : Pearson's value;  $p$ : p values. Proliferation (f), cell viability (g), caspase 3/7 activation (h), and histone-associated DNA fragments (i) of DAOY cells at 48 hours after *JAG1* siRNA treatment or at the indicated time-points compared to control siRNA. Percent decrease in the number of colonies (j) and neuro-spheres (k) formed by DAOY cells 72 and 120 hours, respectively, following *JAG1* siRNA treatment compared to control siRNA. (k, right panel) Representative image of DAOY-derived neuro-spheres upon treatment with *JAG1* siRNA and control siRNA.

has been described as anti-proliferative receptor in MB [17], JAG1 appears to specifically mediate pro-survival NOTCH2 signals in MB.

Indeed, JAG1 depletion negatively affected proliferation rate of MB cells (Figure 2f), and induced activation of the apoptotic machinery through enhanced caspase 3 and 7 activity, which led to an increase in apoptotic histone-associated DNA fragments and reduction of cell viability (Figure 2g, h, and i). Moreover, JAG1-depleted cells were unable to grow clonally (Figure 2j), and the capability of these cells to form neuro-spheres was reduced (Figure 2k), further supporting the notion that JAG1 has a key role in maintaining NOTCH-related pro-survival functions in MB cells.

Altogether, the relevant high expression level of JAG1 in the vast majority of tested MB samples, and the important role in promoting cell proliferation and survival, all pointed at JAG1 as a key player in canonical NOTCH activation and render this NOTCH ligand a potential target for novel selective strategies aimed at NOTCH inhibition in MB.

#### **Molecular subgroup-specific analysis reveals high levels of NOTCH ligand JAG2 in MYC-driven Group 3 tumors**

To date, the distribution and potential role of NOTCH ligands within the defined MB molecular sub-groups is unknown. We therefore examined NOTCH ligands expression levels across sub-groups in two distinct cohorts of MB primary samples with available annotation for molecular subgroups (n = 388) (Figure 3a-d and Additional file 3: Figure S3a-e). On one hand, the analysis confirmed that the overexpression of *JAG1* is a common feature across all four MB molecular subtypes (Figure 3a and Additional file 3: Figure S3a), thus highlighting the potential benefit of targeting JAG1 for the treatment of MB tumors of different origin. On the other hand, the study revealed distinct patterns of expression of other NOTCH ligands across subgroups. In particular, we noticed the presence of a subpopulation of Group 3 cases expressing high *JAG2* levels (Figure 3b and Additional file 3: Figure S3b), in contrast to the previous observation of a broad JAG2 under-expression in MB tumors (Figure 1c). Additionally, we could detect an up-regulation of NOTCH ligand *DLL1* in Group 4 cases (Figure 3c and Additional file 3: Figure S3c), and a down-regulation of *DLL3* in Groups 3 and 4 tumors (Figure 3d and Additional file 3: Figure S3d). No significant differences in *DLL4* expression were observed across the four MB subgroups (Additional file 3: Figure S3e).

Given the established oncogenic role of MYC in Group 3 tumors [23,31] (Additional file 3: Figure S3f), we next sought to investigate the potential correlation between the oncogene MYC and JAG2, whose expression was found unexpectedly high in Group 3 tumors. Strikingly, gene


correlation analysis based on distinct MB gene expression profiles revealed a significant positive correlation of *MYC* and *JAG2* (Figure 3e and Additional file 3: Figure S3g). Furthermore, this correlation in expression was specific for Group 3 MB samples (Figure 3f and Additional file 3: Figure S3h), thus suggesting a link between one particular NOTCH ligand and the oncogene MYC in a molecularly defined patient population. Indeed, a subset of WNT MBs also possess high MYC levels [2] (Additional file 3: Figure S3f), but neither high *JAG2* expression could be detected in this subgroup (Figure 3b), nor MYC and JAG2 levels correlate among these tumors (Additional file 3: Figure S3h, middle panel). The relatively low *JAG2* expression in WNT tumors may reflect either distinct mechanisms regulating NOTCH members in this subgroup and/or a regulatory cross-talk between the WNT and NOTCH pathways in MB.

To further confirm the microarray results on *JAG2*/*MYC* expression correlation, their mRNA levels were analyzed in the same cohort of 47 primary MB samples previously examined for *JAG1* expression. Regrettably, molecular subgroup annotations were not available for this cohort of MB tumors, nevertheless *JAG2* level positively correlated with *MYC* expression (Additional file 3: Figure S3i), thus confirming the previous results and further supporting the hypothesis of the two proteins being functionally linked.

Additionally, to gain a more comprehensive overview, correlation analyses were performed also between *MYC* and the other NOTCH ligands. A slight negative correlation between *MYC* and *DLL1* was noticed (Additional file 3: Figure S3j). On the other hand, no relevant association with MYC level was detected for *JAG1*, *DLL3*, or *DLL4* in primary MB samples (data not shown), thus indicating that the association between *MYC* and *JAG2*, among the NOTCH ligands, is likely exclusive and potentially characteristic of Group 3 tumors.

#### **High JAG2 expression associates with aggressive anaplastic tumors and highly metastatic stages of medulloblastoma**

MYC-driven MB cases (Group 3) have a high risk of recurrence, the worst outcome of the four subgroups, and a high proportion of large cells/anaplastic (LCA) tumors [27]. In comparative studies on tumor samples, as well as *in vitro* and *in vivo* preclinical investigations, the LCA variant has been associated with over-expression of the oncogene MYC and with aggressive and invasive tumor cell behavior [4]. Scoring for the association of the NOTCH ligand JAG2 with MB histological subtypes in distinct datasets with available histological details (n = 364), we detected a significant enrichment of *JAG2* expression in LCA tumors compared to classic and desmoplastic cases (Figure 3g and Additional file 4: Figure S4a).



Notably, the results were similar to those obtained in the study in which the expression level of *MYC* and LCA cases were correlated (Figure 3h and Additional file 4: Figure S4b).

Moreover, because nearly 50% of Group 3 tumors are metastatic at the time of diagnosis [27], we next analyzed whether the expression of *JAG2* is indicative of a higher metastatic stage in MB primary samples. In three datasets with available metastasis details (n = 172), high levels of *JAG2* were observed in highly metastatic MB samples (≥M2 stages) compared to M0 and M1 cases (Figure 3i and Additional file 4: Figure S4c). Although the limited number of highly metastatic tumors reduced

the statistical relevance of these findings, similar results were obtained in the analysis in which *MYC* expression levels were examined together with M stage in the same MB samples (Figure 3j and Additional file 4: Figure S4d). Regrettably, the public datasets with available information about metastatic MB stages do not account for MB sub-grouping signatures, and vice versa. Therefore, we could not verify if high *JAG2* expression correlated with MB metastatic stages in Group 3 cases specifically.

Additionally, analogous analyses examined the expression of the other NOTCH ligands in distinct histological MB subtypes and metastatic stages. However, none of the other ligands could be robustly associated with the

histological features of MB tumors (data not shown). In summary, the positive and specific correlation between *MYC* and *JAG2* for LCA tumors and highly metastatic MB stages is consistent with the Group 3-specific association between *MYC* and *JAG2*. This further strengthens the notion of a functional interaction between these two proteins and suggests that high *JAG2* level may be indicative of aggressive MB tumors.

#### **NOTCH ligand *JAG2* is a *MYC* target gene in medulloblastoma**

Given the extensive evidence correlating *MYC* and *JAG2*, we next investigated in greater detail the mechanistic link between this NOTCH ligand and the oncogene. To assess whether in MB *JAG2* expression is *MYC*-dependent, first we compared *JAG2* and *MYC* levels in a panel of human MB cell lines. Remarkably, *JAG2* expression was high at the mRNA and protein levels in the high-expressing *MYC* cell lines (D341 and D425), whereas *JAG2* levels were lower in the low-expressing *MYC* MB cell lines (DAOY and UW-228) (Figure 4a). *MYC*-dependent *JAG2* expression was experimentally further confirmed in MB cells genetically manipulated to have either increased or decreased *MYC* expression. In MB cells stably transfected with a *MYC* expression construct (DAOY M2.1), both the mRNA and protein levels of *JAG2* were considerably higher compared to wild-type- and empty vector-transfected cells (Figure 4b). Increased *JAG2* expression in M2.1 cells was indeed *MYC*-dependent because *MYC* overexpression-induced *JAG2* levels were blunted following *MYC* depletion by siRNA (Figure 4c). Unexpectedly, after 72 hours of *JAG2* silencing a moderate decrease in *MYC* protein abundance was observed. However, the analysis of *MYC* mRNA level following *JAG2* siRNA showed a very small and statistically in-significant decrease in expression only after 72 hours (Additional file 4: Figure S4e). Because alteration of *MYC* expression did not take place at earlier time-points, these results suggested that the observed effect at the protein level is likely independent of transcriptional regulation.

Furthermore, to verify if the oncogene *MYC* can modulate the transcription of NOTCH ligand *JAG2*, we examined by chromatin immunoprecipitation whether *MYC*, as transcription factor, was bound to the promoter region of *JAG2* in a panel of MB cell lines. Genomic DNA was extracted and precipitated with a *MYC*-specific antibody to enrich *MYC*-binding promoter sequences, which were then hybridized to a promoter oligo-array [29]. An enrichment of DNA fragments surrounding the transcriptional start site of *JAG2* was detected (Figure 4d and Additional file 5: Figure S5a), indicating that *MYC* is indeed able to bind the *JAG2* promoter region and thus potentially capable of modulating its expression. Notably, higher amounts of *MYC* protein were detected at the *JAG2*

promoter in a subset of cell lines with high *MYC* levels (e.g., D341 and D458 cells) compared to those with low *MYC* levels (e.g., DAOY and UW-228). In agreement with recent findings describing *MYC* as a universal amplifier rather than an on-off transcriptional switcher [32], our experimental evidence suggests that in tumor cells expressing high levels of *MYC*, this transcription factor accumulates in the promoter regions of (already) active genes, likely further increasing the levels of transcripts within the cell's gene expression program. Thus, the identification of *JAG2* as *MYC* target gene suggests that constitutive *MYC* induction could be involved in the alteration of NOTCH-related developmental programs in MB.

#### **The oncogene *MYC* alters NOTCH signaling in medulloblastoma**

Finally to evaluate if *JAG2* has a functional role in *MYC*-driven MB pathogenesis, we examined the biological function of *JAG2* in MB cells expressing high levels of *MYC* (DAOY M2.1) [20]. Upon *JAG2* depletion by siRNA transfection in cells with high *MYC* expression (Additional file 5: Figure S5b), the number of cells undergoing apoptosis was slightly increased (Figure 4e), while proliferation concomitantly decreased (Figure 4f). Since *MYC* induction in MB cells leads to an increased proportion of cells undergoing programmed cell death, while overall viability is maintained through higher rate of proliferation [20], our results suggested that *JAG2* might be one of the proteins involved in the regulation of *MYC*-controlled apoptosis or proliferation. However, the mechanism underlying this regulation remains incompletely understood. In fact, the levels of NICD2 and of NOTCH target HES1 were not altered upon *JAG2* silencing (Additional file 5: Figure S5c), indicating that *JAG2* functions are independent of canonical NOTCH cascade activation. Moreover, although *JAG2* depletion in MB cells expressing high levels of *MYC* led to apoptosis and reduced proliferation, unexpectedly, these phenotypical alterations were not mirrored by reduced cell viability (Additional file 5: Figure S5d). Besides, we noticed that *JAG2* depletion caused a significant increase in the relative mRNA and protein levels of *JAG1* (Additional file 5: Figure S5e). Analogous effects were observed when *JAG2* levels were measured under conditions in which *JAG1* was depleted (data not shown). Consistently, MB cell lines with high expression of *JAG2*/*MYC* (D341 and D425; Figure 4a) also displayed lower *JAG1* levels compared to cells expressing low *MYC* levels (DAOY and UW-228; Figure 2b). Thus, it is possible that these two ligands are mutually regulated in a manner in which the high abundance of one ligand represses the expression of the other ligand and vice-versa. Hence, increased *JAG1* expression induced by *JAG2* depletion could provide protection from apoptosis and






Figure 4 (See legend on next page.)

(See figure on previous page.)

**Figure 4 MYC-dependent regulation of NOTCH ligand JAG2 expression.** (a) Relative mRNA expression (upper panel) of *MYC* (black bars, left Y axis) and *JAG2* (orange bars, right Y axis) in the indicated cell lines. Values represent the fold-change in mRNA expression relative to cerebellum (defined as 1). Protein expression (lower panel) of *MYC* and *JAG2* in the corresponding cell lines. (b) Relative mRNA expression (upper panel) of *MYC* and *JAG2* in DAOY cells and stable clones of DAOY V11, and DAOY M2.1 cells. Values represent fold-change in mRNA expression relative to cerebellum (defined as 1). Protein expression (lower panel) of *MYC* and *JAG2* in corresponding cells is shown. (c) *MYC* and *JAG2* mRNA (upper panel) and protein (lower panel) expression in DAOY M2.1 cells transfected with *MYC* siRNA compared to control siRNA. mRNA values represent the percent decrease in *JAG2* and *MYC* expression relative to control. Expression of  $\beta$ -actin was used as a control for western blot analysis. Statistical analysis: black stars indicate p values relative to *MYC* expression; orange stars indicate p values relative to *JAG2* expression. (d) ChIP-on-chip data show occupancy of the *JAG2* genomic sequence by *MYC* in four MB cell lines (from top to bottom: DAOY, UW-228, D458, and D341). (e) Time-dependent caspase 3/7 activation in DAOY M2.1 cells upon *JAG2* siRNA treatment at the indicated time-points; values represent the percent increase in caspase 3/7 activity relative to control. (f) Proliferation status of DAOY cells, DAOY V11, DAOY M2.1, and DAOY M2.1 cells at 48 hours after *JAG2* siRNA treatment compared to control siRNA. Caspase 3/7 activation at 48 hours after treatment with GSI in the indicated cell lines (g) and DAOY-derived clones (h). Low *MYC* cells: DAOY; high *MYC* cells: DAOY M2.1. Values represent the percent increase in caspase 3/7 activity relative to control siRNA.

thereby increase the viability of *JAG2* knocked-down cells. The inverse correlation between *JAG1* and *JAG2* expression was additionally verified by the analysis of MB cells bearing different level of *MYC/JAG2*. In high-*MYC* cells (DAOY M2.1), parallel with the high *JAG2* expression induced by *MYC*, *JAG1* expression was lower (Additional file 5: Figure S5f). Consistently, *JAG1* level increased upon *JAG2* reduction triggered by *MYC* knockdown (Additional file 5: Figure S5g). Interestingly, in cells expressing high levels of *MYC/JAG2*, the expression of the NOTCH target *HES1* was considerably decreased (Additional file 5: Figure S5f), whereas *HES1* expression was up-regulated when *MYC* was absent and *JAG1* was expressed (Additional file 5: Figure S5g). These findings highlighted the key role of *JAG1* in canonical NOTCH activation, and further suggested that *JAG2* signals through a non-canonical NOTCH pathway.

Finally, because *MYC* controls *JAG2* expression and thereby likely alters NOTCH signaling, we sought to determine whether the expression levels of *MYC* in MB cells impact the response to treatment with  $\gamma$ -secretase inhibitor (GSI), a small molecule able to block the NOTCH cascade. Indeed, GSI treatment at concentrations which proved to be effective in inhibiting NOTCH cascade in MB cells [33], showed varying responses in different MB cell lines, correlating with the level of *MYC* expression. MB cells overexpressing *MYC* were less sensitive to treatment-induced apoptosis compared to low *MYC* cells (Figure 4g and h) and, strikingly, sensitivity to GSI-induced apoptosis was restored when *MYC* was depleted (Figure 4h). Altogether these results indicated the existence of a finely tuned regulatory mechanism that results in mutual regulation of *JAG1* and *JAG2* expression in MB cells, and suggested that the oncogene *MYC* is able to influence the NOTCH cascade, at least partially via the transcriptional induction of *JAG2* expression.

## Discussion

This study shed light on the yet unexplored pathological functions of NOTCH ligands in MB, and verified our

main hypothesis that an alteration of NOTCH developmental pathway may be caused by abnormal ligand expression. By examining the expression levels in large cohorts of MB primary tumors and established *in vitro* MB models, we demonstrated the presence of abnormal levels of four distinct NOTCH ligands (*JAG1*, *JAG2*, *DLL1*, and *DLL4*) in MB. By analyzing their patterns of expression across MB molecular subgroups, we showed that NOTCH ligand *JAG1* is broadly over-expressed in MBs, and homogeneously distributed across subgroups. In contrast, *JAG2* is generally under-expressed in tumors compared to normal cerebellum, but a subpopulation of *MYC*-driven MBs bear increased levels of this ligand. Importantly, *MYC/JAG2* correlation is specific for Group 3 cases, therefore suggesting a link between one particular NOTCH ligand and the oncogene *MYC* in a molecularly defined patient population. By identifying *JAG2* as *MYC* target, and by showing that MB cells acquire induced expression of *JAG2* through *MYC*-induced transcriptional activation, we described for the first time a mechanistic link between the oncogene *MYC* and NOTCH pathway in MB. These results are supported by the report from Yustein et al. that described *JAG2* as one of the *MYC* target genes participating in tumorigenesis in a human B cell model [34]. Together with a study describing NOTCH4 as a *MYC* target [35], these two reports represent the only experimental evidence, to our knowledge, for transcriptional control of the NOTCH pathway by *MYC*.

Moreover, the positive and specific correlation of *MYC* and *JAG2* with aggressive anaplastic tumors, and highly metastatic MB stages might represent a clinically relevant finding. Because future stratification of MB patients will likely involve the inclusion of phenotypic tumor cell parameters, these results suggest that determining the expression level of *JAG2* may be helpful for the sub-classification of *MYC*-driven MB to distinguish aggressive tumors from less severe malignancies. From the clinical point of view, these results may also be relevant for current histology-based diagnosis of MB. Indeed, the identification of LCA MB will likely retain its prognostic

significance, even when molecular sub-grouping will more frequently be used in clinics; in this context, JAG2 may represent an additional potential marker for high MYC/LCA MB tumors. Regrettably, the number of MB samples collected in the Children's Hospital of Zurich is too small to conduct a meaningful survival analysis. Moreover, the public datasets of primary MB samples, from where the data for this study was extracted, lack survival data. Therefore, we could not perform a survival analysis comparing patients with or without aberrant JAG1 or JAG2.


In addition, current MB research is intensely focusing on developing accurate mouse models of MYC-driven MB. To overcome MYC-induced apoptosis, two recently developed MYC-driven mouse MB models require loss of p53 [36,37]. Because JAG2 appeared to cooperate with MYC to protect MYC-overexpressing cells from apoptosis, JAG2 induction/up-regulation could be a useful strategy for the development of such high-MYC-expressing MB animal models.

To summarize, we propose a simplified model that illustrates NOTCH signaling induced by JAG1 and JAG2 in MB cells in the context of different levels of MYC (Figure 5). The majority of MB tumors bear low MYC levels and high levels of JAG1, which triggers pro-proliferative signaling through NOTCH2. On the other hand, a subset of MBs, and/or a subset of cells within a given tumor, express high levels of MYC and acquire a concomitantly increased JAG2 protein level, which likely alters the fine-tuned NOTCH signaling cascade.

In line with previous reports showing in different tumor models that the inhibition of NOTCH ligands has proven effective [15,38], our study showed that

interfering with activation of the NOTCH pathway by targeting its ligands may represent a new direction for alternative therapeutic approaches against MB. In particular, targeting JAG1 appears to be a promising strategy. JAG1 is highly expressed in the vast majority of MBs and homogeneously distributed across subgroups; moreover, JAG1 depletion inhibited pro-proliferative NOTCH2 signals and caused a decrease in expression of HES1, which plays a central role in MB pathogenesis [39-42]. Furthermore, NOTCH1-mediated signaling has been associated with activation of an anti-proliferative cascade in MB [17]; therefore, by specifically inhibiting the JAG1-NOTCH2 axis, a survival signaling would be specifically blocked, and side effects due to broad and non-specific NOTCH inhibition could be avoided. Indeed, such treatment would specifically target a cell membrane protein that is overexpressed in MB tumors, but not in normal cerebellum, thus likely reducing treatment-related side effects on the developing brains of children.

Recent approaches attempting to block NOTCH signaling via inhibitors of the  $\gamma$ -secretase have been effective and these compounds are currently being tested in clinical trials for the treatment of brain tumors, including MBs [43]. However,  $\gamma$ -secretase inhibitors developed thus far broadly inhibit  $\gamma$ -secretases and are unable to distinguish individual NOTCH ligand/receptor interactions; as a result, they also affect other pathways [44], and such treatment is associated with intestinal toxicity [45]. Besides, in MB a broad NOTCH inhibition will likely also block anti-proliferative signals induced by the NOTCH1 receptor [17]. These negative, treatment-related consequences could be minimized by therapeutic



**Figure 5 MYC-dependent NOTCH signaling in MB cells.** Simplified scheme illustrating the MYC-dependent NOTCH molecular network involving JAG1 and JAG2 in MB cells. (Left panel) Low MYC MB cell. (Right panel) High MYC MB cell.

strategies specifically targeting individual ligands or receptors. In addition, we observed that the response of MB cells to GSI treatment was influenced by MYC status, although the mechanism remains incompletely understood. Because MYC depletion reduces JAG2 and increases JAG1 expression, thereby shifting cells from non-canonical to canonical NOTCH signaling, it is conceivable that the dependence on canonical NOTCH signaling would be increased. This observation is significant because JAG2 blockage in MYC-driven MB tumors may cause the re-acquisition of tumor sensitivity to treatment with  $\gamma$ -secretase inhibitors.

Therefore, further studies are required to determine the benefits of such treatments in combination with NOTCH ligand inhibition for different MB subtypes, particularly MYC-driven tumors. Additional effort is also needed for the development of neutralizing antibodies and/or small molecules targeting specific NOTCH ligands, which should then be tested in MB animal models to verify the benefits of such treatments.

## Conclusion

This study advanced our understanding of NOTCH signaling and its pathological role in MB, and investigated for the first time the therapeutic benefits of interfering with NOTCH pathway via the inhibition of NOTCH ligands in MB cells. This approach represents an attractive strategy to be considered in combination with targeting SHH or WNT pathways or as a side therapy to synergize with the apoptosis-inducing effects of standard chemo-therapeutics.

## Additional files

**Additional file 1: Figure S1.** Expression of NOTCH ligands in MB primary tumors and cerebellum samples. **(a)** Relative mRNA expression of the indicated NOTCH ligands in two independent gene expression datasets of human MB tumors [Left panel: 57 samples [22]; right panel: 76 samples [26]. **(b)** Relative mRNA expression of the indicated NOTCH ligands in a gene expression profile dataset of human cerebellum samples (n = 9) [28].

**Additional file 2: Figure S2.** JAG1 siRNA-mediated silencing and correlation of JAG1/HES1 in primary MB tumors. **(a)** Relative JAG1 mRNA expression in DAOY cells upon JAG1 siRNA treatment at the indicated time-points. Values represent the percent decrease in JAG1 mRNA relative to the control. **(b)** Correlation between JAG1 and HES1 mRNA expression in three representative datasets of human MB tumors: left panel, 76 samples [26]; middle panel, 57 samples [22]; right panel, 62 samples [23]. r: Pearson's value; p: p values. **(c)** Western blot showing expression of JAG1 and NICD1 in DAOY cells at 48 hours after JAG1 siRNA treatment compared to control siRNA.  $\beta$ -actin expression was used as control.

**Additional file 3: Figure S3.** Validation of the expression of NOTCH ligands across MB molecular subgroups and correlation of MYC/JAG2 expression in MB primary tumors. Dot plots showing the relative expression (log 2) of JAG1 **(a)**, JAG2 **(b)**, DLL1 **(c)**, DLL3 **(d)**, and DLL4 **(e)** across MB subgroups in 285 human MB tumors [24]: SHH, n = 51; Grp3 (Group 3), n = 46; Grp4 (Group 4), n = 188. **(e and f)** Dot plots showing the relative expression of DLL4 and MYC, respectively, across MB subgroups in two datasets. Left panel [25]: SHH, n = 33; WNT, n = 8; Grp3

(Group 3), n = 27; Grp4 (Group4), n = 35. Right panel [24]: SHH, n = 51; Grp3 (Group 3), n = 46; Grp4 (Group 4), n = 188. **(g)** Correlation between MYC and JAG2 mRNA expression in 285 MB tumors [24]. r: Pearson's value; p: p values. **(h)** Correlation study of JAG2 and MYC expression levels (log 2) across MB subgroups (SHH, WNT, Group 4) [25]. **(i)** Correlation between MYC and JAG2 mRNA expression (log 2) in 47 MB primary samples. **(j)** Correlation between MYC and DLL1 mRNA expression in two datasets of 285 MB tumors (left panel) [24] and 103 MB tumors (right panel) [25]. r: Pearson's value; p: p values.

**Additional file 4: Figure S4.** High JAG2 expression in LCA MB tumors and highly metastatic MB cases. Box plots showing JAG2 **(a)** and MYC **(b)** expression (log 2) according to MB histological variants of MB tumors. Left panels (n = 251) [24]: classic (n = 200), desmoplastic (desmop.) (n = 21), and (LCA) large cells/anaplastic (n = 30). Right panels (n = 103) [25]: classic (n = 77), desmoplastic (desmop.) (n = 16), and (LCA) large cells/anaplastic (n = 8); center line = median. Box plots showing JAG2 **(c)** and MYC **(d)** expression in MB tumors clustered by the metastatic stage of MB tumors; center line = median. Left panels (n = 63): M0, n = 45; M1, n = 5; M2, n = 4; M3, n = 9. Right panels (n = 46) [21]: M0, n = 26; M1, n = 7;  $\geq$ M2, n = 13. **(e)** MYC mRNA expression in DAOY M2.1 cells upon JAG2 siRNA at the indicated time-points. mRNA values represent the percent decrease in MYC expression relative to siRNA control.

**Additional file 5: Figure S5.** Validation of MYC-dependent JAG2 expression and compensatory mechanism regulating relative JAG1/JAG2 levels. **(a)** MYC binding to the JAG2 promoter in four additional MB cell lines. ChIP-on-chip data showing occupancy of the JAG2 genomic sequence by MYC in four additional MB cell lines (from top to bottom: D283, ONS76, PNET5, and MED8A). **(b)** Relative JAG2 mRNA expression in MYC stably transfected DAOY M2.1 cells upon JAG2 siRNA treatment at the indicated time-points. **(c)** Western blot showing the expression of JAG2, NICD2, and HES1 in MYC stably transfected DAOY M2.1 cells at 48 hours after JAG2 siRNA treatment compared to control siRNA;  $\beta$ -actin expression was used as a control. **(d)** Cell viability of MYC stably transfected cells (DAOY M2.1) at 48 hours after JAG2 siRNA treatment compared to control siRNA. **(e)** Relative JAG1 and JAG2 mRNA expression (left panel) and protein expression (right panel) in DAOY M2.1 cells at 72 hours after JAG2 siRNA treatment. **(f)** Relative JAG1 and HES1 mRNA expression in DAOY M2.1 MYC stably transfected cells (high MYC) and DAOY V11 empty vector-transfected cells (low MYC). **(g)** Relative JAG1 and HES1 mRNA expression in DAOY M2.1 cells at 48 hours after MYC siRNA compared to control siRNA.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

GF, TS, MB, and MAG, conceived and designed the experiments. GF completed and analyzed all experiments except those specifically listed here. CS and FW provided and analyzed the ChIP-on-chip data. DC and AA assisted with the manuscript. GF, TS, MB, and MAG wrote the manuscript. All authors read and approved the final manuscript.

## Acknowledgements

We thank the Swiss Pediatric Oncology Group (SPOG) for providing MB samples. This research project was supported by Cancer League Zürich, by Swiss Research Foundation Child and Cancer, and the University of Zürich, Forschungskredit (FK-13-039).

## Author details

<sup>1</sup>Department of Oncology, University Children's Hospital of Zurich, Zurich, Switzerland. <sup>2</sup>Department of Tumor Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>3</sup>Department of Clinical Research, University of Bern, Bern, Switzerland.

Received: 31 March 2014 Accepted: 1 April 2014

Published: 7 April 2014

## References

1. Dennis M, Spiegler BJ, Hetherington CR, Greenberg ML (1996) Neuropsychological sequelae of the treatment of children with medulloblastoma. *J Neurooncol* 29:91–101



2. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM (2012) Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathol* 123(4):465–472
3. Gilbertson R (2002) Paediatric embryonic brain tumours: biological and clinical relevance of molecular genetic abnormalities. *Eur J Cancer* 38(5):675–685
4. Gilbertson RJ, Ellison DW (2008) The origins of medulloblastoma subtypes. *Annu Rev Pathol* 3:341–365
5. Fiuza UM, Arias AM (2007) Cell and molecular biology of Notch. *J Endocrinol* 194(3):459–474
6. Yoon K, Gaiano N (2005) Notch signaling in the mammalian central nervous system: insights from mouse mutants. *Nat Neurosci* 8(6):709–715
7. Radtke F, Raj K (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor? *Nat Rev Cancer* 3(10):756–767
8. Bray SJ (2006) Notch signalling: a simple pathway becomes complex. *Nat Rev Mol Cell Biol* 7(9):678–689
9. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S (2012) The Notch signalling system: recent insights into the complexity of a conserved pathway. *Nat Rev Genet* 13(9):654–666
10. D'Souza B, Miyamoto A, Weinmaster G (2008) The many facets of Notch ligands. *Oncogene* 27(38):5148–5167
11. Allenspach EJ, Maillard I, Aster JC, Pear WS (2002) Notch signaling in cancer. *Cancer Biol Ther* 1(5):466–476
12. Zweidler-McKay PA (2008) Notch signaling in pediatric malignancies. *Curr Oncol Rep* 10(6):459–468
13. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA (2010) Notch promotes radioresistance of glioma stem cells. *Stem cells* (Dayton, Ohio) 28(1):17–28
14. Miele L, Miao H, Nickoloff BJ (2006) NOTCH signaling as a novel cancer therapeutic target. *Current cancer drug targets* 6(4):313–323
15. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N, Sarkar FH (2010) Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. *J Cell Biochem* 109(4):726–736
16. Koch U, Radtke F (2007) Notch and cancer: a double-edged sword. *Cell Mol Life Sci* 64(21):2746–2762
17. Fan X, Mikolaenko I, Elhassani I, Ni X, Wang Y, Ball D, Brat DJ, Perry A, Eberhart CG (2004) Notch1 and notch2 have opposite effects on embryonal brain tumor growth. *Cancer Res* 64(21):7787–7793
18. Fiaschetti G, Castelletti D, Zoller S, Schramm A, Schroeder C, Nagaishi M, Stearns D, Mittelbronn M, Eggert A, Westermann F, Ohgaki H, Shalaby T, Pruschy M, Arcaro A, Grotzer MA (2011) Bone morphogenetic protein-7 is a MYC target with pro-survival functions in childhood medulloblastoma. *Oncogene* 30(25):2823–2835
19. Kunkle A, De Preter K, Heukamp L, Thor T, Pajtl KW, Hartmann W, Mittelbronn M, Grotzer MA, Deubzer HE, Speleman F, Schramm A, Eggert A, Schulte JH (2012) Pharmacological activation of the p53 pathway by nutilin-3 exerts anti-tumoral effects in medulloblastomas. *Neuro-oncology* 14(7):859–869
20. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG (2006) c-myc overexpression causes anaplasia in medulloblastoma. *Cancer res* 66(2):673–681
21. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. *J Clin Oncol* 24(12):1924–1931
22. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, Manie E, Raquin MA, Bours D, Carpentier S, Barillot E, Grill J, Doz F, Puget S, Janoueix-Lerosey I, Delattre O (2009) Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. *J Pathol* 218(1):86–94
23. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrcic A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. *PLoS one* 3(8):e3088
24. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stutz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, Dubuc A, Yao Y, Ramaswamy V, Luu B, Rolider A, Cavalli FM, Wang X, Remke M, Wu X, Chiu RY, Chu A, Chuah E, Corbett RD, Hoad GR, Jackman SD et al (2012) Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature* 488(7409):49–56
25. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD (2011) Medulloblastoma comprises four distinct molecular variants. *J Clin Oncol* 29(11):1408–1414
26. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, Chalhoub N, Baker SJ, Huether R, Kriwacki R, Curley N, Thiruvengadam R, Wang J, Wu G, Rusch M, Hong X, Beckwith J, Gupta P, Ma J, Easton J, Vadodaria B, Onar-Thomas A, Lin T, Li S, Pounds S, Paugh S et al (2012) Novel mutations target distinct subgroups of medulloblastoma. *Nature* 488(7409):43–48
27. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S, McCabe M, Collins VP, Backlund ML, Haberler C, Bourdeaut F, Delattre O, Doz F, Ellison DW, Gilbertson RJ, Pomeroy SL, Taylor MD, Lichter P, Pfister SM (2012) Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. *Acta Neuropathol* 123(4):473–484
28. Roth RB, Hevez P, Lee J, Willhite D, Lechner SM, Foster AC, Zlotnik A (2006) Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. *Neurogenetics* 7(2):67–80
29. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA (2010) miR-9, a MYC/MYCIN-activated microRNA, regulates E-cadherin and cancer metastasis. *Nature cell biology* 12(3):247–256
30. Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P et al (2013) Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. *Cell* 152(5):1065–1076
31. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. *J Clin Oncol* 29(11):1424–1430
32. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA (2012) Transcriptional amplification in tumor cells with elevated c-Myc. *Cell* 151(1):56–67
33. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG (2006) Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. *Cancer Res* 66(15):7445–7452
34. Yustein JT, Liu YC, Gao P, Jie C, Le A, Vuica-Ross M, Chng WJ, Eberhart CG, Bergsagel PL, Dang CV (2010) Induction of ectopic MYC target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. *Proc Natl Acad Sci U S A* 107(8):3534–3539
35. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B (2003) Genomic targets of the human c-Myc protein. *Genes Dev* 17(9):1115–1129
36. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ (2012) An animal model of MYC-driven medulloblastoma. *Cancer cell* 21(2):155–167
37. Kawauchi D, Robinson G, Uziel T, Gibson P, Reh J, Gao C, Finkelstein D, Qu C, Pounds S, Ellison DW, Gilbertson RJ, Roussel MF (2012) A mouse model of the most aggressive subgroup of human medulloblastoma. *Cancer cell* 21(2):168–180
38. Nam DH, Jeon HM, Kim S, Kim MH, Lee YJ, Lee MS, Kim KM, Lee DS, Price JE, Bang SI, Park WY (2008) Activation of notch signaling in a xenograft model of brain metastasis. *Clin Cancer Res* 14(13):4059–4066
39. de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R (2008) Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. *J Neurooncol* 10(6):1040–1060

40. Ingram WJ, McCue KI, Tran TH, Hallahan AR, Wainwright BJ (2008) Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling. *Oncogene* 27(10):1489–1500
41. Dakubo GD, Mazerolle CJ, Wallace VA (2006) Expression of Notch and Wnt pathway components and activation of Notch signaling in medulloblastomas from heterozygous patched mice. *J Neurooncol* 79(3):221–227
42. Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, Russell TL, Ellenbogen RG, Bernstein ID, Beachy PA, Olson JM (2004) The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. *Cancer res* 64(21):7794–7800
43. Shih Ie M, Wang TL (2007) Notch signaling, gamma-secretase inhibitors, and cancer therapy. *Cancer res* 67(5):1879–1882
44. Beel AJ, Sanders CR (2008) Substrate specificity of gamma-secretase and other intramembrane proteases. *Cell Mol Life Sci* 65(9):1311–1334
45. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H (2005) Notch/ gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. *Nature* 435(7044):959–963

doi:10.1186/2051-5960-2-39

**Cite this article as:** Fiaschetti *et al.*: NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. *Acta Neuropathologica Communications* 2014 **2**:39.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

